Clinical effectiveness and safety of vildagliptin in >19 000 patients with type 2 diabetes: the GUARD study

• Published in: Diabetes, obesity & metabolism obesity & metabolism, 2015-06, Vol.17 (6), p.603-607
• Main Authors: Rosales, R., Abou Jaoude, E., Al-Arouj, M., Fawwad, A., Orabi, A., Shah, P., DiTommaso, S., Vaz, J., Latif, Z. A.
• Format: Article
• Language: English
• Subjects: Adamantane - analogs & derivatives; Adamantane - therapeutic use; Adult; Aged; Blood Glucose - drug effects; Blood Glucose - metabolism; Body Mass Index; Body Weight - drug effects; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; dipeptidyl peptidase-4 (DPP-4); Drug Therapy, Combination - methods; Female; Glycated Hemoglobin A - drug effects; Glycated Hemoglobin A - metabolism; Humans; Hypoglycemia - chemically induced; Hypoglycemic Agents - therapeutic use; incretins; Male; Metformin - therapeutic use; Middle Aged; Nitriles - therapeutic use; Prospective Studies; Pyrrolidines - therapeutic use; Treatment Outcome; type 2 diabetes; Vildagliptin
• ISSN: 1462-8902; 1463-1326
• DOI: 10.1111/dom.12436

The present GUARD study was a prospective, non‐interventional study evaluating the clinical effectiveness, safety and tolerability of vildagliptin with or without metformin in adult patients with type 2 diabetes mellitus (T2DM) studied in routine clinical practice. Patients were enrolled from countries across four geographical regions. The primary endpoint was change in glycated haemoglobin (HbA1c) concentration from baseline after 24 weeks of treatment with vildagliptin with or without metformin. Of 19 331 patients analysed, 3511 received vildagliptin and 15 820 received vildagliptin plus metformin. At week 24, the mean HbA1c was reduced significantly from baseline by −1.27% (vildagliptin: −1.17%; vildagliptin plus metformin: −1.29%; p